Allogenica Wins €2.5M to Transform CAR-T Cancer Treatment

Allogenica, a pioneering biotech company, has secured a €2.5 million grant under France’s Innovations in Biotherapies and Bioproduction for France 2030 program. This funding will drive the industrialization of its universal CAR-T therapy, XL-001, designed to make life-saving cancer treatments more accessible and affordable. Unlike traditional CAR-T therapies, which rely on patient-derived cells, Allogenica’s approach uses donor stem cells, cutting costs and simplifying the production process. By expanding access to advanced immunotherapies, the company is helping thousands of leukemia and lymphoma patients who previously faced limited treatment options.

“This funding is a game-changer for Allogenica and the future of CAR-T therapies,” said Dr. Inna Menkova, CEO of Allogenica. “With this support, we can take XL-001 from lab to clinic, ensuring more patients receive treatment without delays.” The CAR-T market is expected to reach €21 billion by 2030, and Allogenica is at the forefront of this revolution. By industrializing its scalable platform, the company aims to treat up to 30,000 patients annually while reinforcing France’s leadership in biopharmaceutical innovation.